Study of Clinical Efficacy and Safety of Tosedostat in MDS
Status:
Completed
Trial end date:
2017-10-25
Target enrollment:
Participant gender:
Summary
Study WCMC IST-CTI-MDS evaluates the safety and tolerability of tosedostat in adult patients
with pathologically confirmed MDS (< 20% blasts in bone marrow, peripheral blood, or both) by
World Health Organization (WHO) classification after failure of hypomethylating agent-based
therapy.